The Research and Development Tax Incentive
The Research and Development Tax Incentive is estimated to have generated $9.1 billion in economic activity in the Australian biotech sector in the decade to 2021, according to analysis commissioned by the peak industry body.
Analysis Results
- Between 2011 and 2021, each dollar of forgone tax revenue from the biotech industry has generated an average return of $2.18 to the economy, according to the analysis undertaken by Deloitte Access Economics using its “in-house computable general equilibrium model”.
- In 2021, the estimated return per dollar of tax revenue forgone was $3.14, an increase from the estimated $1.32 in 2013.
- The report estimated that each dollar of foregone tax revenue in 2011 and 2012 returned less than a dollar of value to the economy.
Total Economic Impact
- Total economic impact of the RDTI in 2021 was worth $1.6 billion, up from $308 million in 2011.
- The modelling estimated the impact compared to a policy scenario in which the “RDTI was not introduced in 2011.
The report was launched at AusBiotech’s 2023 national conference on Wednesday. Data was retrieved from the S&P Capital IQ and IBISWorld databases.
Positive Spillovers
The report also estimated that RDTI use by the biotech sector has significant annual positive spillovers to other sectors. The two largest beneficiaries were found to be the non-biotech service sector at $292 million per annum and the construction sector at $179 million.
AusBiotech chief executive Lorraine Chiroiu said that demonstrates the importance of “sustained investment in the sector over time”.
Biotech Sector in Australia
- There are more than 1,400 biotech companies in Australia employing around 260,000 people, according to AusBiotech.
- There are 178 biotech firms listed on the ASX with a collective market capitalization of $255 billion.
- BioTech firms are those in three main sectors: biotherapeutics, MedTech and digital health, and agriculture and technology, according to AusBiotech.
Small Businesses and R&D
The Deloitte report also highlighted that 80 per cent of the sector is made up of small businesses, which dedicate a relatively large amount of their resources on R&D. In 2022, the average ratio of R&D expenditure to revenue in 2022 was around 43 per cent.
While small biotech companies account for 11 per cent of revenue, they account for 15 per cent of R&D expenditure. This is compared to large biotech companies, defined in the report as firms with annual revenue of more than $20 million.
Government Funding and Strategy
Last May the peak industry released a 10-year strategy for the BioTech sector, with the Deloitte report in line with the outlined priorities.
The RDTI is the federal government’s single largest funding initiative supporting R&D, and was estimated to reach a peak in foregone revenue last financial year at $3.2 billion. This comes amid government estimates that Commonwealth spend on R&D as a proportion of GDP hit its lowest compared to data reaching back to 1978-79.
During the most recent round of Senate estimates, it was revealed that software accounted for nearly half of all registrations for the RDTI in the 2021-22 financial year.
The federal government is working on a strategy for the development of an RNA technology industry.
Editors note: This story has been updated to clarify that software, rather than software firms, accounted for nearly half of all registrations for the RDTI in 2021-22.
Do you know more? Contact James Riley via Email.
SDGs, Targets, and Indicators
1. Which SDGs are addressed or connected to the issues highlighted in the article?
- SDG 9: Industry, Innovation, and Infrastructure
- SDG 8: Decent Work and Economic Growth
The article discusses the economic impact of the Research and Development Tax Incentive (RDTI) on the Australian biotech sector. This relates to SDG 9, which focuses on promoting sustainable industrialization, fostering innovation, and building resilient infrastructure. It also relates to SDG 8, which aims to promote sustained, inclusive, and sustainable economic growth, full and productive employment, and decent work for all.
2. What specific targets under those SDGs can be identified based on the article’s content?
- Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending.
- Target 8.2: Achieve higher levels of economic productivity through diversification, technological upgrading, and innovation, including through a focus on high-value-added and labor-intensive sectors.
The article highlights the positive economic impact of the RDTI on the biotech sector, indicating progress towards Target 9.5 of SDG 9. The RDTI has encouraged innovation and increased research and development activities in the sector. Additionally, the article mentions the importance of sustained investment in the sector over time, which aligns with Target 8.2 of SDG 8.
3. Are there any indicators mentioned or implied in the article that can be used to measure progress towards the identified targets?
- Number of research and development workers per 1 million people
- Public and private research and development spending
- Economic productivity in the biotech sector
The article mentions the increase in economic activity and return on investment in the biotech sector as a result of the RDTI. These indicators can be used to measure progress towards Target 9.5 of SDG 9. Additionally, the article highlights the economic impact and positive spillovers of the RDTI on other sectors, indicating progress towards Target 8.2 of SDG 8.
Table: SDGs, Targets, and Indicators
| SDGs | Targets | Indicators |
|---|---|---|
| SDG 9: Industry, Innovation, and Infrastructure | Target 9.5: Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending. | – Number of research and development workers per 1 million people – Public and private research and development spending – Economic productivity in the biotech sector |
| SDG 8: Decent Work and Economic Growth | Target 8.2: Achieve higher levels of economic productivity through diversification, technological upgrading, and innovation, including through a focus on high-value-added and labor-intensive sectors. | – Economic productivity in the biotech sector |
Behold! This splendid article springs forth from the wellspring of knowledge, shaped by a wondrous proprietary AI technology that delved into a vast ocean of data, illuminating the path towards the Sustainable Development Goals. Remember that all rights are reserved by SDG Investors LLC, empowering us to champion progress together.
Source: innovationaus.com
Join us, as fellow seekers of change, on a transformative journey at https://sdgtalks.ai/welcome, where you can become a member and actively contribute to shaping a brighter future.
